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ABSTRACT 
A STUDY ON DETECTION OF MACROLIDE RESISTANCE GENES OF 
Streptococcus pneumonia ISOLATED FROM PATIENTS IN HOSPITAL USM AND 
ITS CLINICAL OUTCOMES 
 
Introduction 
Streptococcus pneumoniae is one of the leading pathogen causing pneumonia, meningitis, 
bacteremia and bacterial otitis media worldwide. It cause more serious disease in young 
patients less than 5 years old, elderly aged more than 65 years and in patients with   
underlying medical condition such as malignancy, chronic obstructive airway disease, 
chronic liver disease, chronic renal disease, diabetes mellitus and smokers. Global increase 
in antibiotic resistance in S.pneumoniae remains a serious concern worldwide. In global 
multi-country study of antimicrobial susceptibility in S. pneumoniae, revealed that regional 
rates of antibiotic resistance were consistently the highest in Asia. The dramatic increase in 
in-vitro resistance of S.pneumoniae, particularly beta-lactams and macrolide antibiotic 
raised the questions on clinical impact of antimicrobial resistance on clinical outcomes.  
The aim of this study is to describe the clinical characteristics and outcome of S. 
pneumoniae infection, antibiotic susceptibility pattern, distribution of macrolide-resistance 
determinants and its relationship with macrolides susceptibility pattern and clinical 
outcomes among patients in Hospital Universiti Sains Malaysia, Kelantan. 
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Methodology 
This is a descriptive cross sectional study conducted in Hospital Universiti Sains Malaysia. 
S.pneumoniae, in which non-duplicate isolates were collected from various clinical 
specimens from June 2014 to December 2015. Susceptibility to six antibiotics i.e 
penicillin, erythromycin, azithromycin, vancomycin, trimetophrim-sulfamethoxazole and 
amoxycillin-clavulanic acid were determined using E-test strips (BioMerieux SA, France). 
The results were interpreted according to CLSI guidelines. All isolates were subjected to 
polymerase chain reaction (PCR) analysis to detect macrolide-resistance determinants. 
Patients' clinical data including demographic, clinical diagnosis, risk factors, and outcomes 
were obtained from clinical notes.  
Results 
A total of 113 patients with positive growth of S. pneumoniae from clinical samples were 
included in the study. Community-acquired pneumonia is the predominant presentation of 
pneumococcal infection.  Penicillin resistance rate was 7.1%, with MIC ranging between 
0.012 – >32 µg/ml and MIC90 of 1µg/ml. Approximately 26.5% of the isolates resistant to 
erythromycin with MIC range of 0.03 – >256 1µg/ml and MIC90 of 32 µg/ml. Among the 
erythromycin-resistant isolates, majority were found to have mef(A) gene (50.4%), erm(B) 
gene (20%), 16.7% with combination of mef(A) and erm(B) and 13.3% with none of the 
two genes. There were no significant association between presence of macrolide resistance 
determinants with mortality (p = 0.837) or complications (p > 0.999 for empyema and 
cardiac complication; p = 0.135 for subdural abscess) 
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Conclusion 
Overall, the isolates showed good susceptibility towards all antibiotics tested except for 
azithromycin. The outcome and complications of pneumococcal diseases were not 
significantly different between macrolide-resistance than those with macrolide-susceptible 
groups and were not affected by the presence of macrolide resistance determinants in the 
pneumococcal isolates. 
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ABSTRAK 
KAJIAN PENGESANAN GEN RINTANGAN MACROLIDE DALAM Streptococcus 
pneumoniae YANG DI ISOLAT DARI PESAKIT DI HOSPITAL USM DAN 
KAITAN DENGAN KESAN KLINIKAL 
 
Pengenalan 
Streptococcus pneumoniae adalah salah satu patogen utama yang menyebabkan jangkitan 
paru-paru, jangkitan selaput otak, jangkitan dalam darah dan jangkitan pada telinga tengah 
di seluruh dunia. Jangkitan adalah lebih serius dalam kalangan pesakit muda berumur 
kurang dari 5 tahun, warga tua yang berumur lebih daripada 65 tahun dan juga pesakit 
yang mempunyai masalah perubatan yang sedia ada seperti kanser, penyakit saluran 
pernafasan yang kronik, penyakit hati kronik, penyakit buah pinggang kronik, kencing 
manis dan perokok. Peningkatan secara global kerintangan antibiotik dalam kalangan S. 
pneumoniae menjadi kebimbangan yang serius di seluruh dunia. Satu kajian yang 
melibatkan pelbagai negara melaporkan bahawa kadar rintangan antibiotik dalam kalangan 
S. pneumoniae secara konsisten adalah paling tinggi di rantau Asia. Peningkatan dramatik 
rintangan S. pneumoniae in-vitro, terutamanya terhadap antibiotik beta-lactams dan 
macrolide membangkitkan persoalan mengenai kesan klinikal rintangan antibiotik terhadap 
hasil klinikal.  
Tujuan kajian ini adalah untuk menggambarkan ciri-ciri klinikal dan kesan klinikal 
jangkitan S. pneumoniae, corak sensitiviti antibiotik, dan menentukan hubungkait antara 
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gen rintangan - macrolide dengan corak sensitiviti terhadap macrolides dan kesan klinikal 
dalam kalangan pesakit di Hospital Universiti Sains Malaysia, Kelantan. 
Tatacara 
Kajian irisan lintang deskriptif ini dijalankan di Hospital Universiti Sains Malaysia. Isolat 
S. pneumoniae, bukan pendua dari pelbagai spesimen klinikal dikumpul dari Jun 2014 
hingga Disember 2015. Sensitiviti terhadap enam antibiotik iaitu penisilin, erythromycin, 
azithromycin, vancomycin, trimetophrim-sulfamethoxazole dan amoxycillin-clavulanic 
acid telah dijalankan menggunakan ujian E-test ( bioMérieux SA, Perancis). Keputusan 
telah ditafsirkan mengikut garis panduan CLSI. Ujian tindakbalas rantai polimer (PCR) 
telah dijalankan untuk mengesan penentu rintangan macrolide. Data klinikal pesakit 
termasuk data demografi, diagnosa klinikal, faktor-faktor risiko, dan kesan klinikal 
diperolehi daripada nota klinikal. 
 Keputusan 
Seramai 113 pesakit dengan kultur dari sampel klinikal positif untuk S. pneumoniae telah 
dimasukkan dalam kajian ini. Klinikal manifestasi jangkitan pneumokokal yang utama 
adalah jangkitan pada paru-paru. Kadar kerintangan terhadap penicillin adalah 7.1%, 
dengan MIC antara 0.012 - > 32 μg / ml dan MIC90 ialah 1μg / ml. 26.5% isolat rintang 
terhadap eryhromycin dengan MIC antara 0.03 - > 256 1μg / ml dan nilai MIC90 daripada 
32 μg / ml. Majoriti (50.4%) isolat yang rintang terhadap erythromycin mempunyai gen 
mef(A). Isolat yang mempunyai hanya gen erm(B) dan kombinasi kedua-dua mef(A) dan 
erm(B)  adalah masing-masing 20% dan 16.7%.  Manakala isolat yang tidak mempunyai 
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kedua-dua gen adalah 13.3%. Didapati tidak ada hubungkait yang signifikan antara 
kehadiran gen rintangan macrolide dengan kematian (p = 0.837) atau komplikasi ( p > 
0.999 untuk empyema dan komplikasi jantung; p = 0.135 untuk subdural abscess ) 
 
Kesimpulan 
Secara keseluruhan, isolat menunjukkan tahap sensitiviti yang baik terhadap semua 
antibiotik yang diuji kecuali azithromycin. Kesan klinikal dan komplikasi penyakit 
pneumokokal tidak berbeza secara signifikan antara pesakit yang sensitif terhadap 
macrolide daripada mereka yang rintang terhadap macrolide, dan tidak terjejas dengan 
kehadiran gen penentu rintang macrolide di dalam isolat pneumokokal. 
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 CHAPTER 1 
INTRODUCTION 
1.1 Background of the study 
Streptococcus pneumoniae (pneumococcus) is one of the leading causes of the mortality 
and morbidity worldwide. In 2005, World Health Organization (WHO) estimated that 
1.6 million deaths were caused by this agent annually, where 0.7- 1 million are children 
aged less than 5 years. S. pneumoniae is a Gram positive bacteria, spread by airborne 
droplets and is a primary causes of bacterial pneumonia, acute otitis media, sinusitis and 
bacteraemia and meningitis worldwide. It causes more serious infection in infants less 
than 3 years old and in adults older than 65 years old (Wardlaw et al., 2006). 
Conditions that predispose to pneumoccoccal diseases include underlying medical 
condition such as malignancy, asthma, chronic obstructive airway disease, diabetes 
mellitus and smoking. Approximately 10% of all patients with invasive pneumococcal 
disease die due to their illness but case-fatality rates are higher for the elderly and 
patient with underlying medical conditions.   
WHO estimates that in the Asia Pasific region, 49 out of 98 cases of pneumonia deaths 
in children are due to pneumococcal pneumonia. In Malaysia, 4% of the 7000 deaths 
among children less than 5 years old were estimated due to pneumococci (incidence of 
overall pneumonia deaths of 10.2 out of 10,000 children aged under 5 years (Rohani et 
al., 1999b).
 
Several studies done in Malaysia found that pneumonia is the most common 
pneumococcal disease in Malaysia (Rzeszutek et al., 2004; Lim et al., 2007; Rohani et 
al., 2011). 
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For pneumococcal infections, antibiotics are one of the choices of treatment. However, 
several studies have shown that in recent years, there has been dramatic increased in the 
prevalence of antibiotic resistance in S. pneumoniae particularly against those of the 
first line antibiotics such as penicillin, as well as to macrolide antibiotics such as 
erythromycin, that makes pneumoccocal infections difficult to treat especially in 
children and elderly (Song et al., 2004a). Asian Network for Surveillance of Resistant 
Pathogens (ANSORP) study 2004 previously has reported an alarming increase of 
erythromycin resistant S. pneumoniae. In some Asian countries, the reported prevalence 
of penicillin and macrolide resistance was the highest in the world (Song et al., 2004b). 
Macrolides act by binding to the 23S subunit of the 50S ribosome, by attaching at 
domain V of the peptidyl transferase loop, thereby blocking protein synthesis (Mandell 
et al., 2014). There are two commonly described mechanisms for macrolide resistance. 
The first one is target site modification in the 23S rRNA of the large 50S ribosomal 
subunit by a ribosomal methylase encoded by the erm (B) (erythromycin ribosome 
methylation) genes on plasmids or transposons on chromosomes that are self-
transferable, resulting in decreased binding of the antibiotics to targets on the ribosome. 
The second mechanism is by drug efflux system encoded by the mef (A) gene 
(macrolide efflux), a transposable element, and consists of transmembrane domains 
across the cytoplasmic membrane. This efflux pump confer resistance by excludes 
macrolides from the bacterium.  
The disease burden of pneumococcal infections has increased due to widespread 
emergence of antimicrobial resistance in many countries during the past few decades. 
The increased resistance rate to penicillin and macrolide caused the treatment for 
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pneumococcal diseases complicated and difficult. Previous surveillance studies showed 
that more than 60% of pneumococcal isolates from Asian countries were resistant to 
erythromycin and 22.7% were penicillin-resistant (Kim et al., 2012; Song et al., 1999).  
Infectious Diseases Society of America/American Thoracic Society recommended 
macrolides as a drug of choice for empiric therapy of community-acquired pneumonia 
(CAP) for outpatient treatment in previously healthy and low-risk patient, and in 
patients with comorbidities or use of antimicrobials within the previous 3 months, beta-
lactam plus a macrolide was strongly recommended. For patients requiring 
hospitalization, a parenteral beta-lactam (with or without a macrolide) was advocated 
(Mandell et al., 2007). Data confirm that macrolide resistance in pneumococci is a 
serious problem in many Asian countries including in Malaysia during the past few 
decades. This complicated the treatment for pneumococcal diseases and increased the 
disease burden. However, data specifically evaluate the impact of macrolide resistance 
on clinical outcomes are scarce. 
An Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study, Song et 
al. (2004b), found out that bacteremia and mechanical ventilation were significant risk 
factors for death, but any kind of antibiotic resistance was not associated with increased 
mortality due to pneumococcal pneumonia. However, in this study, the number of 
patients from each participating country was relatively small, and the quality of clinical 
care were different in each participating center, therefore the findings were not 
represent the overall status of the clinical characteristics or the final outcome in each 
country. 
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1.2 Rationale of the study 
Because of the frequency and importance of pneumococcal infections in our population, 
and with increasing prevalence of macrolide-resistant S. pneumoniae, the clinical 
impact of resistant strain should be further clarified specifically in our country. To our 
knowledge, there is no study yet that describe the association between the macrolide 
resistance determinants with the clinical outcomes. Therefore, the aim of this study is to 
determine the clinical characteristic  and clinical outcomes of pneumococcal infections 
caused by macrolide-resistant S. pneumoniae, specifically in relation to the presence of 
macrolide- resistance determinant genes, as well as to determine the proportion of 
macrolide resistant genes and current antibiotic susceptibility pattern of common 
antibiotic used against S. pneumoniae in our population that can be served as 
surveillance data in our country. 
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1.3 Literature Review 
1.3.1 History and taxonomy of Streptococcus pneumoniae (S. pneumoniae/ 
pneumococcus) 
Streptococcus pneumoniae was first described independently by two microbiologist, 
Louis Pasteur in France and George M. Sternberg from United States in 1881 and was 
named as  Microbe septicemique du salive by Pasteur and Micrococcus pasteuri by 
Sternberg (Watson et al., 1993). By 1886, the organism was called as Pneumococcus 
because of its ability to cause pulmonary disease, then was renamed as Diplococcus 
pneumoniae in 1920 by Winslow et al. (1920)  because of its characteristic appearance 
in Gram stain and later on given its present name as Streptococcus pneumoniae  in 1974 
based on its characteristic growth as chains of cocci in liquid medium (Edward 
N.Janoff, 2015).  
S. pneumoniae is classified under the order of Lactobacillales, family of 
Streptococcaceae, genus of Streptococcus and species of S. pneumoniae. There are 
currently 97 serotypes of S.pneumoniae known, distinguished by the polysaccharide 
capsular structure (Geno et al., 2015).  
1.3.2 Epidemiology 
Streptococcus pneumoniae is one of the leading pathogen worldwide causing 
pneumonia, meningitis, bacteremia and bacterial otitis media. Pneumonia is the leading 
cause of death of children, accounting for 1 in 5 deaths, and S. pneumoniae is the 
leading cause of bacterial childhood pneumonia (Bennett et al., 2015). Pneumococcal 
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diseases including pneumonia, sepsis, and meningitis are the leading cause of bacterial 
deaths in young children, causing up to one million deaths per year in those younger 
than 5 years (O'Brien et al., 2009).  
Invasive pneumococcal disease (IPD), defined as isolation of S. pneumoniae from a 
normally sterile site, examples blood, cerebrospinal fluid (CSF), surgical aspirate; 
pleural, pericardial, peritoneal, bone, or joint fluid. IPD commonly affects young 
children aged less than two years and adult aged  ≥ 65 years and case fatality rate higher 
in immunocompromised individuals, elderly and patients with certain underlying 
diseases (CDC, 2010).  
In Malaysia, a 5 year retrospective study at Universiti Malaya Medical Centre done by 
Nur et al. (2008) examining patients in all age groups identified S. pneumoniae as the 
major causative agent in bacterial meningitis (23.4%), and other study also reported that 
S. pneumoniae is one of the leading pathogens (8 out of 58; 13.8%) in childhood 
meningitis following H. influenzae type B accounting for 48.3% (Hussain et al., 1998). 
In another study done in Kuala Lumpur, the percentage of S. pneumoniae isolated from 
adult patients with community-acquired pneumonia was 13.2% (Liam, 2005).  In a 
study that investigated childhood IPD, pneumonia was the most common type of IPD in 
children younger than 14 years of age (Lim et al., 2007).  
1.3.3 Streptococcus pneumoniae colonization 
Children are the main carriers of Streptococcus pneumoniae (Bogaert et al., 2004; 
Hussain et al., 2005). The organism begins to colonize the nasopharynx as early as first 
week of life. The prevalence of colonization increases from less than 10% to a peak at 
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70% to 100% at age one year, persists through the third year of life, and decreases 
thereafter to adult rates of approximately 10% depending on the sampling location, 
methods, and culture (Benin et al., 2003).  
In one cohort study that investigated the age-dependent carriage rate in healthy children 
and adolescents aged 1–19 years, the peak incidence of pneumococcal colonisation was 
at the age of 3 years (55%) then steadily decline and stable at rate of 8% after the age of 
10 years old (Bogaert et al., 2004). 
In the United States, a prospective study has shown that generally pneumococci 
colonize an infant at around 6 months of age and can be detected for a mean of about 4 
months (Gray and Dillon, 1988). The individual serotype can persist from one week to 
6 months, but in adults, the serotype persists for shorter periods, usually two to 4 weeks 
(Ekdahl et al., 1997), but can be longer up to several months (Heffron R., 1979).  
The risk factors for nasopharyngeal carriage in young children included day care center 
attendance and having young siblings (Regev-Yochay et al., 2004), while for adolescent 
and adults the risk factors include acute upper respiratory tract infection, cigarette 
smoking and asthma (Cardozo et al., 2008). Ethnicity, crowding, environmental, and 
socioeconomic factors such as income also contributed to the risk of nasopharyngeal 
carriage of S. pneumoniae. (Bogaert et al., 2004).  
1.3.4  Risk factors for pneumococcal infection 
Factors that predispose to pneumococcal infection include conditions that leads to 
defective antibody formation, whether primary (congenital) such as 
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agammaglobulinaemia, common variable agammaglobulinaemia  or secondary 
(acquired), example multiple myeloma, chronic myeloid leukaemia and HIV infection 
(Bennett et al., 2015). Defective complement pathway and insufficient number or 
defective function of polymorphonuclear leukocyte as seen in patient with alcoholism, 
liver cirrhosis, diabetes mellitus, renal disease and glucocorticoid treatment were also 
associated with increased risk of getting pneumococcal disease.  
Other risk factors for invasive pneumococcal disease include asplenia, age more than 65 
years, underlying chronic lung diseases and prior respiratory viral infection (van der 
Poll and Opal, 2009). Nosocomial pneumonia caused by Streptococcus pneumoniae 
following any cause of hospitalization also had been reported. Other factors include 
crowding, alcoholism, cigarette smoking, poverty and recent use of antibiotic may 
contribute to pneumococcal disease (Kim et al., 1996). 
The risk of invasive pneumococcal disease in closed populations and in the community 
may be reduced by the widespread use of pneumococcal vaccine  (Albrich et al., 2007; 
Valenzuela et al., 2007).  
1.3.5 Virulence factors and pathogenesis 
Nasopharyngeal colonization of S. pneumoniae is required for transmission of bacteria 
and development of invasive disease (Weinberger et al., 2008). Pneumococci bind to 
mucosal epithelial cells of the nasopharynx and caused disease by contiguous spread to 
the sinuses or middle ear causing sinusitis or otitis media, aspiration into the lung 
causing pneumonia, or invasion of the bloodstream causing septicaemia (Bogaert et al., 
2004; Tuomanen et al., 1995) 
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The pathogenesis of pneumococcal infection is a complex interplay between 
pneumococcal virulence determinants and the host immune response. This virulence 
determinants and the corresponding immune responses produce four key effects that 
involved in the pathogenesis of pneumococcal diseases; adhesion, invasion, 
inflammation and shock (Gillespie and Balakrishnan, 2000). 
Pneumococcal capsule is the most important virulence factor for pneumococcal and 
play a crucial role during colonisation, invasion, and dissemination from the respiratory 
tract (Nelson et al., 2007). Capsular polysaccharide avoid ingestion and killing by host 
phagocytic cells (Edward N.Janoff, 2015; Musher, 1992), inhibits complement and 
immunoglobulin-binding to host receptors (van der Poll and Opal, 2009), and also 
enhances pneumococcal colonization by limiting mucus-mediated clearance (Nelson et 
al., 2007).  
Virtually all S. pneumoniae expressed pneumolysin (Kadioglu et al., 2008) which is 
cytotoxic to host phagocytic and respiratory epithelial cells and have the ability to 
inhibit ciliary action of epithelial cells. (Zhang et al., 2007).  
1.3.6 Clinical significance 
S.pneumoniae can directly spread from the nasopharyngeal site of colonization and 
causes infection of the middle ear, lung, bronchi, and sinuses. The organism may spread 
hematogenously to the heart, bones and joint. Infection to the pleural, peritoneal cavity 
and central nervous system may occur by direct extension or hematogenous route 
(Bennett et al., 2015).  
10 
 
S. pneumoniae is a major cause of community-acquired pneumonia (CAP) accounting 
up to 36% of adult community-acquired pneumonia. In the United States, estimated that 
as many as 400,000 hospitalizations occur annually are due to pneumococcal 
pneumonia (CDC, 2015b). The risk for serious disease is higher in older adults because 
they usually have underlying medical conditions such as chronic obstructive pulmonary 
disease, malignancy, heart disease, liver disease and diabetes (Edward N.Janoff, 2015; 
Laurichesse et al., 2001).  
Complications of pneumococcal pneumonia include pleural effusion, empyema, lung 
abscess, and less common are pericarditis and endocarditis (Musher, 1992). In 
Malaysia, CAP also the main clinical manifestation of pneumococcal infections, 
followed by sepsis, otitis media, and conjunctivitis. Most of the patients aged 50 years 
or more had preexisting chronic conditions such as current or treated pulmonary 
tuberculosis, chronic obstructive airway diseases, asthma or lung cancer (Rohani et al., 
1999b). 
S. pneumoniae is also a common cause of bacteremia and meningitis in children and 
adults (Winn and Koneman, 2006). Among elderly patients, case-fatality rate for 
pneumococcal bacteremia range from 20% to as high as 60% among elderly patients. 
(CDC, 2015b). 
S. pneumoniae also a leading cause of acute otitis media in children (Block, 1997; 
Bluestone et al., 1992). Complications of acute pneumococcal otitis media include 
mastoiditis, bacteremia and tympanic membrane perforation (Kouppari et al., 2000). 
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Treatment failures for acute otitis media due to multidrug-resistant S pneumoniae have 
been reported (Pichichero and Casey, 2007).   
1.3.7 Antibiotic resistance 
In global multi-country studies of antimicrobial susceptibility in S. pneumoniae, an 
Asian Network for Surveillance of Resistant Pathogens (ANSORP) study by Kim et al. 
(2012) revealed that regional rates of antibiotic resistance were consistently the highest 
in Asia. Isolates that had the highest resistance rates generally are from China, Hong 
Kong, South Korea, Taiwan, Thailand and Vietnam (up to 92%).  
Macrolides are one of the choice of treatments for the infection caused by S. 
pneumoniae, especially for empirical therapy for patient with CAP in outpatient setting 
(Mandell et al.,2007; MOH., 2014) . However in recent years, there is an alarming 
increased in resistant rate of S.pneumoniae towards macrolide antibiotics in the world 
including Malaysia were reported in the literature. In China, erythromycin resistance 
rates for S. pneumoniae increased from 35-53% in 1996-1999, to over 75% by 2001 and 
South Korea showed that resistant rate to erythromycin remained high over period of 
1996-2001 (75-85%). While in Malaysia, 54 out of 165 isolates (32%) were resistant to 
erythromycin in year 2012 (Kim et al., 2012). 
Resistance to macrolides antibiotic occur by several mechanisms in which two major  
mechanisms are by modification of the  target site (ribosomal), mediated by erm(B) 
gene usually carried on conjugative transposons, which may facilitate rapid 
dissemination of erythromycin resistance. The second major mechanism is active 
(proton-dependent) efflux, which encoded by mef(A) genes and can be transferred by 
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conjugation (Lynch and Martinez, 2002). Erm(B) gene caused methylation at the 
macrolide-binding site of the 23S rRNA results in high-level resistance (≥ 64 µg/mL) 
compared to efflux pump encoded by the mef(A) that usually confer low level 
resistance (≤16 µg/mL) (Edward N.Janoff, 2015).  
 A study by Song et al. (2004a) reported that ribosomal methylation encoded by erm(B) 
was the most common mechanism of erythromycin resistance in China, Taiwan,Sri 
Lanka and Korea, while in Hong Kong, Singapore, Thailand and Malaysia, efflux pump 
encoded by mef(A) gene was more common. Erm(B) was found in more than 50% of 
pneumococcal isolates either alone or in combination with mef(A) in most Asian 
countries except Hong Kong, Malaysia and Singapore.  
A previous local study reported that among 71 isolates, 25 (35.2%) isolates were 
erythromycin susceptible, 3 (4.2%) were intermediate and 42 (60.6%) were resistant. 
Mef(A) alone was found in 53 isolates (74.7%), followed by combination of both 
mef(A) and erm(B) gene in 15 (21.1%). Three (4.2%) isolates have none of the two 
genes. Isolates with both mef(A) and erm(B) showed very high MICs to erythromycin   
( ≥ 256 µg/mL) (Nathan et al., 2013).  
The rapid increase in the prevalence of macrolide resistance worldwide including Asian 
countries are due to widespread use of macrolides in clinical practice (Felmingham et 
al., 2007; Kim et al., 2012) and because of clonal spread of macrolide-resistant strains 
(Kim et al., 2012).  
Penicillin resistance in S. pneumoniae is caused by structural changes in penicillin-
binding proteins (PBP) results in reduced affinity for penicillin and other beta-lactam 
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antibiotics (Linares et al., 1992). Six PBPs have been identified in S. pneumoniae 
including PBPs 1a, 1b, 2a, 2b, 2x and 3, where the majority of the resistance are caused 
by  PBP 1a, 2x and 2b (Lynch and Zhanel, 2005). ANSORP study in 2012 reported a 
decrease in the prevalence of penicillin resistance in non-meningeal pneumococci 
whereby only 4.6% were non-susceptible to penicillin and fully resistance only found in 
China (2.2%) and South Korea (0.3%). All 142 non-meningeal pneumococci isolated 
from Malaysia were sensitive to penicillin. Whilst for the meningeal isolates, 23.1% 
were resistant (Kim et al., 2012). From local data, incidence of penicillin resistance was 
increase from two per cent in 1985 (Cheong et al., 1988), to 10.9% in 1997 (Rohani et 
al., 1999a), and 31.78% in 2009 (Rohani et al., 2011). A more recent study that 
investigated 255 clinical isolates collected from 2005-2010 reported a higher resistant 
rate which was 50.2% (Arushothy et al., 2016).  
The ANSORP group also reported a high rate of resistance to trimethoprim-
sulfamethoxazole (50.2%) among S. pneumoniae in Asian countries (Kim et al., 2012). 
Resistance occur due to mutations in the dihydrofolate reductase (dhfr) gene (Lynch 
and Zhanel, 2009a). In Malaysia, resistance to trimetophrim-sulfamethoxazole was 
reported to range from 22% to 44% (Kim et al., 2012; Nathan et al., 2013; Rohani et 
al., 2011).  
Vancomycin-resistant S. pneumoniae have not been reported (Kim et al., 2012; Zhanel 
et al., 2003). However, the emergence of vancomycin tolerance (the ability of bacteria 
to survive but not proliferate in the presence of a bactericidal antibiotic) in S. 
pneumoniae have been described in the previous studies (McCullers et al., 2000; Novak 
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et al., 1999).  In Malaysia, none of the S. pneumoniae isolates investigated in previous 
studies showed resistance to vancomycin (Rohani et al., 2011). 
Prior antibiotic exposure is the major risk factor for amplification of resistance, and 
clonal spread facilitates dissemination of drug-resistant strains (Lynch and Martinez, 
2002).  Macrolide use was the single most important factor for the emergence of 
macrolide resistance in vivo (Malhotra-Kumar et al., 2007) 
Although antibiotic resistance among S. pneumoniae was noted increasing in trend 
worldwide, the clinical significance of in vitro resistance is controversial (Lynch and 
Martinez, 2002; Lynch and Zhanel, 2005). In a matched case-control study of patients 
with bacteremic pneumococcal infection, a  breakthrough bacteremia during macrolide 
therapy was observed among patients infected with an erythromycin-resistant 
pneumococcus, thus indicate that in vitro macrolide resistance is clinically relevant 
(Lonks et al., 2002).  Several studies reported a similar mortality rates of invasive 
pneumococcal diseases due to macrolide-resistant or macrolide-susceptible strains  
(Moreno et al., 1995).  
 
1.3.8 Laboratory identification of Streptococcus pneumoniae 
1.3.8.1 Microscopy 
S. pneumoniae is a Gram-positive cocci occuring in pairs (diplococci) or short chain. 
The cocci are about 1 µm in diameter, ovoid in shape with their distal end narrowed 
(lancet-shaped). They are non-motile and non-sporing (Edward N.Janoff, 2015).  
 
1.3.8.2 Culture 
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S. pneumoniae is an aerobic and facultative anaerobic organism, grows best in the air 
with 5-10% carbon dioxide (CO2), at an optimum temperature of 37
O
C. The organism 
grows well on media with 5-10% serum, blood or heated blood which supplies the 
nutrients, pH buffer and catalase (Ross, 1996). On blood agar, the colonies are small, 
smooth, transparent and surrounded by greenish zone of α-haemolysis. Initially the 
colonies are tiny, convex then become flat or depressed centrally called „draughtsman 
colonies‟ after 24-48 hour of incubation (Reller et al., 2008). Some strain may produce 
very large capsule and form larger mucoid colony (Ross, 1996).  
 
Figure 1: Streptococcus pneumoniae growth on sheep blood agar showed 
“draughtsman” colonies with Optochin disc showed zone of inhibition  
(Adapted from Reller et al. (2008) )  
 
The mainstay of diagnostic tests are Gram stains and microbiological cultures (Lynch 
and Zhanel, 2009b). Examination of sputum samples before antibiotics were 
administered and performance of culture within 24 hour of antibiotic therapy yielded 
16 
 
the correct diagnosis in more than 80% of pneumococcal pneumonia cases (Musher et 
al., 2004)  
 
 1.3.8.3 Biochemical test 
S. pneumoniae produce catalase negative and oxidase negative reaction. They can be 
identified in the laboratory by two reactions: susceptibility to optochin (ethyl 
hydrocuprein hydrochloride), and solubility in bile salts (sodium deoxycholate).   
 
Optochin susceptibility test 
Susceptibility to Optochin provides a reliable and simple test to differentiate 
S.pneumoniae from viridans streptococci.  Five µg of optochin disc is placed on a blood 
agar or MHBA plate that has been confluently spread with a broth suspension of 
suspected S.pneumoniae colonies, incubate at 37
O
C in a 5-10% CO2 incubator (Ross, 
1996). A zone of inhibition of 14mm or more around a 6-mm disc indicates 
susceptibility to optochin and the organism can presumptively identifies as S. 
pneumoniae. If the zone of inhibition is smaller than 14mm, other alternative 
identification test (e.g., bile solubility) should be performed because some of the 
viridans streptococci may show small zone of inhibition (Winn and Koneman, 2006). 
Optochin susceptibility test was reported to have sensitivity of 100% and specificity of 
98-100% (Chandler et al.,2000., JA Kellogg et al.,2001).  Optochin-resistant 
S.pneumoniae have been reported but rarely encountered (Fenoll et al., 1990).  
 
Bile solubility test 
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Bile salts (Sodium deoxycholate) is capable to lyse S.pneumoniae selectively when 
added to actively growing bacteria in agar or broth media. Bile salts activates the 
autolytic enzymes (pneumolysin) of S.pneumoniae and accelerate their natural lytic 
reaction observed with culture (Winn and Koneman, 2006). Clearing of broth 
suspension containing S.pneumoniae colonies with addition of sodium deoxycholate 
indicate that the organism is bile-soluble.  
Bile solubility is very sensitive and specific for identification of S. pneumoniae, 100% 
and 99% respectively (Kellogg et al., 2001). S. pneumoniae can be differentiated from 
other viridans streptococci by optochin susceptibility and bile solubility, whereby S. 
pneumoniae isolates are typically susceptible to optochin and are bile soluble, whereas 
streptococci viridans are typically resistant to optochin and are bile insoluble (Reller et 
al., 2008)  
 
1.3.4.4 Other method 
Rapid test 
Pneumococcal antigen detection such as latex agglutination test is available for rapid 
detection of S.pneumoniae. It is widely used for the diagnosis of pneumococcal 
meningitis (Samra et al., 2003) and rapid detection of S. pneumoniae in blood culture 
(Altun et al., 2016). This method is easy to perform with sensitivity of 99.6–100 % and 
specificity of 64 - 98 %, respectively (Altun et al., 2016). Rapid 
immunochromatographic test (ICT) that detects the polysaccharide cell wall antigen of 
S. pneumoniae (NOW S. pneumoniae urinary antigen test; Binax) is also available. It 
has a sensitivity of 70%–80% and a specificity of more than 90% if applied to urine 
samples (Briones et al., 2006; Rosón et al., 2004). 
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Semi-automated/ automated system method 
Several semi-automated and automated systems are commercially available for 
identification of S. pneumoniae, and reported to produce acceptable identification 
results (Brigante et al., 2006). Semi-automated systems include Vitek 2 system 
(bioMérieux Vitek, USA), Phoenix system (Becton Dickinson Diagnostic Systems, 
Sparks, MD) and MicroScan WalkAway-96 System (Dade Behring). In one study, 
Vitek 2 system correctly identified 96.9% of S. pneumoniae and one of the accurate and 
acceptable means for performing identification and antibiotic susceptibility tests for 
medically relevant Gram-positive cocci (Ligozzi et al., 2002). 
Example of automated system is Vitek MS Matrix-Assisted Laser Desorption 
Ionization- Time of Flight Mass Spectrometry System (Vitek MS MALDI-TOF). The 
sensitivity and specificity of the Vitek MS MALDI-TOF for the identification of S. 
pneumoniae are 99.1% and 100% respectively and the performance is similar to that of 
the optochin susceptibility test for routine identification of pneumococcal isolates 
(Dubois et al., 2013).  
 
Nucleic acid amplification test (NAAT) 
Nucleic acid amplification test such as polymerase chain reaction (PCR) have been used 
to detect S.pneumoniae DNA in blood, sputum and other body fluids such as bronchio-
alveolar lavage and cerebrospinal fluid. In a patient with a pneumococcal pneumonia, 
PCR using blood specimen has a wide range of sensitivity ranging from 29% to 100%. 
Whilst when using sputum samples, PCR was reported to have higher positivity rate 
ranging from 68% to 100% (Murdoch, 2004). Pneumolysin (ply), lytA and psa(A) gene 
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were used as specific targets for detection of S. pneumoniae DNA. Ply gene is also 
present in some viridans streptococci. Thus, the use of this gene can lead to false 
detection of pneumococci. LytA and psaA genes were the most specific for the detection 
S. pneumoniae (Maria da Gloria et al., 2007).  
 
1.3.9 Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing is very important as it can confirm susceptibility to 
the antimicrobial agent chosen and guide the clinician to the appropriate empirical 
treatment, as well as to detect the resistance in bacterial isolates (Reller et al., 2009). 
There are several methods of antimicrobial susceptibility test for bacteria available, 
which include dilution method that based on minimum inhibitory concentration (MIC) 
and disk diffusion method that measure zone of inhibition. MIC is the minimal 
concentration of an antimicrobial agent ( in microgram/milliliter)  required to inhibit or 
kill the microorganism (Jorgensen and Turnidge, 2015). It is the least amount of 
antimicrobial that will inhibit visible growth of an organism after overnight incubation 
(Miles and Amyes, 1996). Automated commercial methods also available such as Vitek 
2 (bioMerieux, Durham, NC), Phoenix (BD,Sparks, MD) and MicroScan ( Siemens 
Healthcare Diagnostics, Deerfil, IL).  
 
The broth macrodilution, broth microdilution, agar dilution and disk diffusion methods 
are the reference methods based on Clinical and Laboratory Standard Institute (CLSI). 
The results of susceptibility test are interpreted according to CLSI interpretive criteria 
that categorized into susceptible, intermediate and resistant. Susceptible category is 
defined as when the bacterial isolates are inhibited by the antimicrobial agent when 
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recommended dosage is used. Isolates with MIC in intermediate category show lower 
response rate compare to susceptible isolates but shows clinical efficacy when higher 
than normal dosage of drug are used. The bacterial isolates are considered resistant 
when they are not inhibited by the usual dosage of drug scheduled. 
 
1.3.9.1 Disk Diffusion method  
In this method, agar plate is uniformly inoculated with the standardized inoculum of test 
organism. A paper disk impregnated with a fixed concentration of antibiotic then is 
placed on the agar surface and incubated under suitable conditions. The antibiotic then 
diffuses into the agar and inhibits the growth of the organism producing zone of 
inhibition that is measured to determine the sensitivity. 
 
This test is simple, does not required special equipment, the result is easy for 
interpretation, and able to test large number of microorganism and antimicrobial agent 
(Balouiri et al., 2016), and the least costly of all susceptibility methods (Reller et al., 
2009). However, the disadvantages are  it inability to distinguish between bactericidal 
and bacteriostatic effect because inhibition of the bacterial growth does not necessarily 
mean bacterial death (Balouiri et al., 2016) and lack of automation of the test (Reller et 
al., 2009). The method need to be standardized as zone of inhibition is largely affected 
by inoculum size, quality of medium or agar plate used, incubation condition and 
technical staff performance. Antimicrobial agents such as vancomycin, polymyxin, and 
macrolides such as clarithromycin have higher molecular weights and therefore diffuse 
poorly in an agar plate (Schwalbe et al., 2007). These poor diffusion combine with 
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poorly resolved concentration gradient around these disks can cause inaccurate reading 
of the results.  
 
1.3.9.2 Antimicrobial gradient method (E-test) 
This method determines the susceptibility of the antimicrobial agents by establishment 
of an antimicrobial concentration gradient in an agar medium. Etest® (bioMe´rieux AB 
Biodisk) is one of the commercialized test consists of a predefined gradient of antibiotic 
concentrations on a plastic strip used to determine the MIC of antimicrobial agent. In 
this method, the strip that is impregnated with increasing concentration gradient of an 
antimicrobial agents is placed on surface of agar plate that has been inoculated with 
tested microorganism.  
 
After an overnight incubation, the MIC is determined by reading a value at the 
intersection of the strip and the growth inhibition ellipse. The advantages of the test is it 
simple and easy to be done and have flexibility of testing the drug that chosen by the 
laboratory. However one of the limitations of the Etest is it‟s high cost. This method is 
expensive if many drugs are to be tested (Reller et al., 2009). This method is best used 
if only need to test one or two drugs or when testing a fastidious organism that require a 
special incubation conditions, example is when testing sensitivity of S.pneumoniae to 
penicillin  (Jorgensen et al., 1994).  
 
 
 
1.3.9.3 Broth dilution method 
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Broth macrodilution method is one of the earliest method for antimicrobial 
susceptibility testing (Reller et al., 2009). The twofold dilutions of antibiotic are 
prepared, and an adjusted bacterial inoculum is added to each tube containing the 
antimicrobial agent. The MIC is the lowest concentration of antimicrobial agent that 
completely inhibits growth of the organism in the tubes as detected by the unaided eye 
(Coyle, 2005). The advantage of this method is the generation of a quantitative result. 
The major disadvantages are the tedious, manual task of preparing the antibiotic 
solutions for each test, the possibility of errors in preparation of the antibiotic solutions, 
and the relatively large amount of reagents and space required for each test (Reller et 
al., 2009). 
 
Broth microdilution MIC testing is performed in a polystyrene panel make a broth 
dilution technique more practical and popular (Reller et al., 2009). The standard tray 
contains 96 wells and contains 7–8 dilutions of 12 different antimicrobial agents 
(Coyle, 2005).  The advantages of this method include the generation of MICs, the 
reproducibility and convenience of having preprepared panels, and the economy of 
reagents and space that occurs due to the miniaturization of the test. The main 
disadvantage is because of some inflexibility of drug selections available in standard 
commercial panels (Reller et al., 2009). 
 
1.3.10 Treatment and prevention 
Infectious Diseases Society of America suggested that for management of community-
acquired pneumonia in adults in outpatient setting, a macrolide (azithromycin, 
clarithromycin, or erythromycin) are recommended for previously healthy and no risk 
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factors for drug-resistant S. pneumoniae (DRSP) infection. A b-lactam plus a macrolide 
are preferred for patients with comorbidities, such as chronic heart, lung, liver, or renal 
disease, diabetes mellitus,  alcoholism, malignancies or other risks for infection caused 
by DRSP. Whilst for patients that required hospitalization, a respiratory 
fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin) or a b-lactam plus a 
macrolide are strongly recommended (Mandell et al., 2007).  
 
Pneumococcal strains from patients requiring hospitalization should undergo antibiotic 
susceptibility test because of increasing antibiotic resistance worldwide and 
susceptibilities to standard agents are no longer assured (van der Poll and Opal, 2009).  
Non-meningeal S pneumoniae strains with intermediate or high-level resistance to 
penicillin can still be treated with high-dose, β-lactam antibiotics (penicillins, or second 
or third generation cephalosporins (Woodhead et al., 2005). Whilst for the meningeal 
strain with even intermediate resistance, use of other agents are necessary to assure a 
successful outcome (Mandell et al., 2007). 
 
There are two types of pneumococcal vaccine currently available in Malaysia, includes 
polysaccharide vaccine (PPV) (Pneumo 23 Polyvalent Vaccine from Sanofi Pasteur and  
Pneumovax 23 Vaccine from Merck Sharp & Dohme) and conjugate vaccine (PCV) 
(Prevenar-13 from Pfizer) (Victor K E Lim, 2014). Pneumococcal polysaccharide 
vaccine consists of the 23 most common capsular serotypes that cause invasive 
pneumococcal disease (Bogaert et al., 2004), poorly immunogenic in children less than 
two years old, compared to PCV that highly immunogenic in young children (Millar et 
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al., 2008). The incidence of pneumococcal diseases in all age group markedly reduced 
by the  widespread use of conjugate vaccine (CDC, 2015a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
